Hunter Smith Sells 4,385 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Hunter Smith sold 4,385 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $101.26, for a total transaction of $444,025.10. Following the transaction, the chief financial officer directly owned 110,512 shares in the company, valued at approximately $11,190,445.12. The trade was a 3.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Rhythm Pharmaceuticals Price Performance

Rhythm Pharmaceuticals stock opened at $99.78 on Friday. Rhythm Pharmaceuticals, Inc. has a 12-month low of $45.90 and a 12-month high of $122.20. The stock has a market capitalization of $6.66 billion, a PE ratio of -32.19 and a beta of 2.00. The firm has a 50 day simple moving average of $105.41 and a 200-day simple moving average of $103.30.

Wall Street Analyst Weigh In

RYTM has been the subject of several research analyst reports. The Goldman Sachs Group upped their price objective on Rhythm Pharmaceuticals from $141.00 to $157.00 and gave the company a “buy” rating in a report on Friday, December 12th. Canaccord Genuity Group boosted their price target on shares of Rhythm Pharmaceuticals from $114.00 to $141.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Morgan Stanley restated an “overweight” rating and set a $150.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Thursday, December 11th. Oppenheimer cut shares of Rhythm Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 5th. Finally, TD Cowen reiterated a “buy” rating on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Rhythm Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $131.50.

Rhythm Pharmaceuticals News Roundup

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: RBC/ Royal Bank initiated coverage and/or upgraded RYTM with an outperform/moderate-buy stance, bringing renewed institutional attention and a formal buy-style endorsement that can support near-term demand. RBC initiates coverage
• Positive Sentiment: Several sell-side firms have raised price targets and reiterated buy/overweight ratings (Wells Fargo, Morgan Stanley, Citizens/JMP, UBS, TD Cowen), reinforcing a bullish consensus and higher upside expectations. MarketBeat analyst roundup
• Positive Sentiment: Operational narrative improving: a Yahoo Finance piece highlights Imcivree revenue ramp and updated management targets — if execution continues, this supports medium-term revenue growth that underpins analyst optimism. Imcivree revenue and targets
• Neutral Sentiment: Zacks moved coverage from “strong sell” to “hold” and flagged RYTM as positioned to potentially beat upcoming earnings — these are watchpoints that reduce perceived downside but are not immediate catalysts without reported results. Zacks coverage and earnings outlook
• Negative Sentiment: Insider selling by CFO Hunter C. Smith: filings show sales of several thousand shares (transactions reported for Feb. 17 and Feb. 19 at ~ $101 per share). While the amounts are a small percentage of his total holding, such sales can trigger near-term selling pressure or investor concern about insider conviction. CFO sale disclosure

Institutional Trading of Rhythm Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC grew its position in Rhythm Pharmaceuticals by 956.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 13,254 shares of the company’s stock worth $1,339,000 after purchasing an additional 12,000 shares in the last quarter. EFG Asset Management North America Corp. acquired a new stake in shares of Rhythm Pharmaceuticals in the third quarter worth $2,047,000. Penserra Capital Management LLC acquired a new stake in shares of Rhythm Pharmaceuticals in the third quarter worth $3,073,000. Norges Bank purchased a new position in shares of Rhythm Pharmaceuticals during the second quarter valued at $13,105,000. Finally, SG Americas Securities LLC grew its holdings in shares of Rhythm Pharmaceuticals by 216.2% during the third quarter. SG Americas Securities LLC now owns 19,554 shares of the company’s stock valued at $1,975,000 after buying an additional 13,369 shares in the last quarter.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.